Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive top-line growth in 2025.Amgen also has some key pipeline assets in obesity ...

in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court. "We have considered Regeneron's remaining arguments and find them unpersuasive," the appeals court wrote ...

As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...

Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but somewhat expected” for Regeneron (REGN). While extended timelines for an additional appeal is likely ...

Eylea, which Regeneron Pharmaceuticals ... The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedic, interventional solutions ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

Regeneron prioritizes returning capital to shareholders. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co ...